Bliss GVS Pharma Limited (BOM:506197)
India · Delayed Price · Currency is INR 519.50
-4.55 (-0.87%)
At close: Aug 17, 2026
Bliss GVS Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 10,052 | 9,271 | 8,097 | 7,702 | 7,516 | 7,475 | |
Revenue Growth | 20.59% | 14.50% | 5.13% | 2.48% | 0.55% | 29.49% |
Cost of Revenue | 4,704 | 4,478 | 4,305 | 4,007 | 4,136 | 4,031 |
Gross Profit | 5,349 | 4,793 | 3,792 | 3,695 | 3,380 | 3,444 |
Selling, General & Admin | 2,126 | 2,006 | 1,498 | 1,394 | 1,160 | 1,045 |
Other Operating Expenses | 1,226 | 1,141 | 1,022 | 795.34 | 1,047 | 1,212 |
Operating Expenses | 3,704 | 3,482 | 2,815 | 2,453 | 2,394 | 2,431 |
Operating Income | 1,644 | 1,311 | 977.58 | 1,242 | 986.49 | 1,013 |
Interest Expense | -71.15 | -120.07 | -81.2 | -60.51 | -98.64 | -36.93 |
Interest & Investment Income | 167.47 | 167.47 | 153.06 | 117.9 | 75.05 | 88.18 |
Currency Exchange Gain (Loss) | 517.8 | 517.8 | 160.06 | 111.35 | 77.69 | 200.57 |
Other Non Operating Income (Expenses) | -232.09 | 26.45 | 46.94 | 44.93 | 16.48 | 14.99 |
EBT Excluding Unusual Items | 2,026 | 1,903 | 1,256 | 1,456 | 1,057 | 1,280 |
Gain (Loss) on Sale of Investments | 9 | 9 | 4.87 | 1.72 | - | - |
Gain (Loss) on Sale of Assets | 14.58 | 14.58 | -4.92 | 2.86 | 3.65 | 0.68 |
Asset Writedown | -5.42 | -5.42 | - | - | - | -3.06 |
Other Unusual Items | -24.87 | -24.87 | - | -291.96 | - | -735.95 |
Pretax Income | 2,020 | 1,896 | 1,256 | 1,169 | 1,061 | 541.65 |
Income Tax Expense | 602.23 | 548.62 | 353.84 | 352.94 | 293.37 | 310.39 |
Earnings From Continuing Operations | 1,417 | 1,347 | 902.55 | 815.78 | 767.35 | 231.27 |
Net Income to Company | 1,417 | 1,347 | 902.55 | 815.78 | 767.35 | 231.27 |
Minority Interest in Earnings | -55.5 | -55.99 | -59.56 | -61.24 | -58.76 | -80.86 |
Net Income | 1,362 | 1,291 | 842.99 | 754.54 | 708.59 | 150.4 |
Net Income to Common | 1,362 | 1,291 | 842.99 | 754.54 | 708.59 | 150.4 |
Net Income Growth | 27.71% | 53.18% | 11.72% | 6.49% | 371.13% | -78.04% |
Shares Outstanding (Basic) | 106 | 106 | 105 | 104 | 104 | 103 |
Shares Outstanding (Diluted) | 108 | 108 | 106 | 106 | 105 | 105 |
Shares Change | 1.93% | 1.47% | -0.04% | 0.56% | 0.26% | -0.26% |
EPS (Basic) | 12.88 | 12.23 | 8.02 | 7.23 | 6.83 | 1.46 |
EPS (Diluted) | 12.62 | 12.00 | 7.95 | 7.11 | 6.72 | 1.43 |
EPS Growth | 25.28% | 50.94% | 11.81% | 5.80% | 369.93% | -77.97% |
Free Cash Flow | - | 818.87 | 296.27 | 744.87 | -594.86 | 614.78 |
Free Cash Flow Per Share | - | 7.61 | 2.79 | 7.02 | -5.64 | 5.84 |
Dividend Per Share | - | 1.500 | 0.500 | 0.500 | 0.500 | 0.500 |
Dividend Growth | - | 200.00% | 0% | 0% | 0% | 0% |
Gross Margin | 53.21% | 51.70% | 46.83% | 47.98% | 44.98% | 46.07% |
Operating Margin | 16.36% | 14.14% | 12.07% | 16.13% | 13.13% | 13.55% |
Profit Margin | 13.55% | 13.93% | 10.41% | 9.80% | 9.43% | 2.01% |
Free Cash Flow Margin | - | 8.83% | 3.66% | 9.67% | -7.92% | 8.22% |
EBITDA | 1,922 | 1,583 | 1,227 | 1,479 | 1,160 | 1,166 |
EBITDA Margin | 19.12% | 17.07% | 15.16% | 19.20% | 15.43% | 15.60% |
D&A For EBITDA | 277.53 | 271.99 | 249.85 | 236.6 | 173.54 | 152.62 |
EBIT | 1,644 | 1,311 | 977.58 | 1,242 | 986.49 | 1,013 |
EBIT Margin | 16.36% | 14.14% | 12.07% | 16.13% | 13.13% | 13.55% |
Effective Tax Rate | 29.82% | 28.94% | 28.16% | 30.20% | 27.66% | 57.30% |
Revenue as Reported | 10,529 | 10,006 | 8,462 | 7,990 | 7,694 | 7,789 |
Advertising Expenses | - | 72.74 | 72.5 | 84.27 | 61.7 | 48.05 |